The US Food and Drug
Administration (FDA) has approved
Cyramza (ramucirumab) for use in
patients with advanced stomach
cancer or gastroesophageal
junction adenocarcinoma.
The treatment was an
angiogenesis inhibitor which
blocked blood supply to tumours,
the FDA said, and was intended for
patients whose cancer could not be
surgically removed or had spread.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.